Page 54 - GPD-3-4

Gene & Protein in Disease Immune checkpoint blocker and NK cell activation

12. Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade (KIRs): Their role in NK cell modulation and developments
with cemiplimab in advanced cutaneous squamous-cell leading to their clinical exploitation. Front Immunol.
carcinoma. N Engl J Med. 2018;379(4):341-351. 2019;10:1179.
doi: 10.1056/NEJMoa1805131 doi: 10.3389/fimmu.2019.01179
13. Shirley M. Avelumab: A review in metastatic merkel cell 24. Sun H, Sun C. The rise of NK cell checkpoints as promising
carcinoma. Target Oncol. 2018;13(3):409-416. therapeutic targets in cancer immunotherapy. Front
Immunol. 2019;10:2354.
doi: 10.1007/s11523-018-0571-4
doi: 10.3389/fimmu.2019.02354
14. Paz-Ares L, Spira A, Raben D, et al. Outcomes with
durvalumab by tumour PD-L1 expression in unresectable, 25. McWilliams EM, Mele JM, Cheney C, et al. Therapeutic
stage III non-small-cell lung cancer in the PACIFIC trial. CD94/NKG2A blockade improves natural killer
Ann Oncol. 2020;31(6):798-806. cell dysfunction in chronic lymphocytic leukemia.
Oncoimmunology. 2016;5(10):e1226720.
doi: 10.1016/j.annonc.2020.03.287
doi: 10.1080/2162402x.2016.1226720
15. Liebl MC, Hofmann TG. Identification of responders
to immune checkpoint therapy: Which biomarkers 26. Seo H, Kim BS, Bae EA, et al. IL21 therapy combined with
have the highest value? J Eur Acad Dermatol Venereol. PD-1 and Tim-3 blockade provides enhanced NK cell
2019;33 Suppl 8:52-56. antitumor activity against MHC class I-deficient tumors.
Cancer Immunol Res. 2018;6(6):685-695.
doi: 10.1111/jdv.15992
doi: 10.1158/2326-6066.cir-17-0708
16. Guo L, Zhang H, Chen B. Nivolumab as programmed
death-1 (PD-1) inhibitor for targeted immunotherapy in 27. Seo H, Jeon I, Kim BS, et al. IL-21-mediated reversal of NK
tumor. J Cancer. 2017;8(3):410-416. cell exhaustion facilitates anti-tumour immunity in MHC
class I-deficient tumours. Nat Commun. 2017;8:15776.
doi: 10.7150/jca.17144
doi: 10.1038/ncomms15776
17. Sinner F, Pinter M, Scheiner B, et al. Atezolizumab plus
bevacizumab in patients with advanced and progressing 28. Deng W, Gowen BG, Zhang L, et al. Antitumor
hepatocellular carcinoma: Retrospective multicenter immunity. A shed NKG2D ligand that promotes natural
experience. Cancers (Basel). 2022;14(23):5966. killer cell activation and tumor rejection. Science.
2015;348(6230):136-139.
doi: 10.3390/cancers14235966
doi: 10.1126/science.1258867
18. du Rusquec P, de Calbiac O, Robert M, Campone M, Frenel JS.
Clinical utility of pembrolizumab in the management of 29. Luo Q, Luo W, Zhu Q, et al. Tumor-derived soluble MICA
advanced solid tumors: An evidence-based review on the obstructs the NKG2D pathway to restrain NK cytotoxicity.
emerging new data. Cancer Manag Res. 2019;11:4297-4312. Aging Dis. 2020;11(1):118-128.
doi: 10.2147/cmar.s151023 doi: 10.14336/ad.2019.1017
19. Kim N, Kim HS. Targeting checkpoint receptors and 30. Ames E, Canter RJ, Grossenbacher SK, et al. NK cells
molecules for therapeutic modulation of natural killer cells. preferentially target tumor cells with a cancer stem cell
Front Immunol. 2018;9:2041. phenotype. J Immunol. 2015;195(8):4010-4019.
doi: 10.3389/fimmu.2018.02041 doi: 10.4049/jimmunol.1500447
20. O’Sullivan TE, Sun JC, Lanier LL. Natural killer cell memory. 31. Cai X, Zhan H, Ye Y, et al. Current progress and future
Immunity. 2015;43(4):634-645. perspectives of immune checkpoint in cancer and infectious
diseases. Front Genet. 2021;12:785153.
doi: 10.1016/j.immuni.2015.09.013
doi: 10.3389/fgene.2021.785153
21. Cao Y, Wang X, Jin T, et al. Immune checkpoint molecules
in natural killer cells as potential targets for cancer 32. Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-
immunotherapy. Signal Transduct Target Ther. 2020;5(1):250. checkpoint inhibitors: Long-term implications of toxicity.
Nat Rev Clin Oncol. 2022;19(4):254-267.
doi: 10.1038/s41392-020-00348-8
doi: 10.1038/s41571-022-00600-w
22. Thielens A, Vivier E, Romagné F. NK cell MHC class I specific
receptors (KIR): from biology to clinical intervention. Curr 33. Pardoll DM. The blockade of immune checkpoints in cancer
Opin Immunol. 2012;24(2):239-245. immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
doi: 10.1016/j.coi.2012.01.001 doi: 10.1038/nrc3239
23. Pende D, Falco M, Vitale M, et al. Killer Ig-like receptors 34. Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and

Volume 3 Issue 4 (2024) 6 doi: 10.36922/gpd.3804